Evolution of eligibility criteria for non-transplant randomized controlled trials in adults with acute myeloid leukemia.
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
09
05
2022
accepted:
27
05
2022
revised:
25
05
2022
pubmed:
7
6
2022
medline:
4
8
2022
entrez:
6
6
2022
Statut:
ppublish
Résumé
Eligibility criteria for clinical trials are intended to select suitable study subjects but can limit trial participation and generalization of results. While reported for other cancers, non-enrollment rates and evolution of eligibility criteria over time have so far not been studied for randomized controlled trials (RCTs) involving adults with acute myeloid leukemia (AML). Among 3698 studies published between 2010 and 2020, including 447 involving prospective clinical trials, we identified 75 phase three RCTs testing non-transplant therapies for adults with AML. Only 31 studies (41%) provided information on non-enrollment; in these studies, the median non-enrollment rate was 23%, primarily attributed to restrictive eligibility criteria. In 95% of trials, eligibility criteria were reported with the total number per trial increasing over time (P < 0.001), particularly in industry-funded trials. A total of 27 eligibility criteria were used across trials, mostly concerning comorbidities or performance status, with eight of them becoming more common over time. The concordance with recent ASCO - Friends of Cancer Research eligibility criteria recommendations greatly varied, from 35% to 99%. Together, our analyses suggest that the ability to generalize results from non-transplant RCTs may be increasingly limited because of high non-enrollment rates and increasingly restrictive eligibility criteria.
Identifiants
pubmed: 35660798
doi: 10.1038/s41375-022-01624-y
pii: 10.1038/s41375-022-01624-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2002-2008Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Giantonio BJ. Eligibility in cancer clinical research: the intersection of discovery, generalizability, beneficence, and justice. Clin Cancer Res. 2021;27:2369–71.
doi: 10.1158/1078-0432.CCR-21-0085
Srikanthan A, Vera-Badillo F, Ethier J, Goldstein R, Templeton AJ, Ocana A, et al. Evolution in the eligibility criteria of randomized controlled trials for systemic cancer therapies. Cancer Treat Rev. 2016;43:67–73.
doi: 10.1016/j.ctrv.2015.12.006
Garcia S, Bisen A, Yan J, Xie X-J, Ramalingam S, Schiller JH, et al. Thoracic oncology clinical trial eligibility criteria and requirements continue to increase in number and complexity. J Thorac Oncol. 2017;12:1489–95.
doi: 10.1016/j.jtho.2017.07.020
Unger JM, Vaidya R, Hershman DL, Minasian LM, Fleury ME. Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation. JNCI J Natl Cancer Inst. 2019;111:245–55.
doi: 10.1093/jnci/djy221
Unger JM, Hershman DL, Fleury ME, Vaidya R. Association of patient comorbid conditions with cancer clinical trial participation. JAMA Oncol. 2019;5:326.
doi: 10.1001/jamaoncol.2018.5953
Harvey RD, Bruinooge SS, Chen L, Garrett-Mayer E, Rhodes W, Stepanski E, et al. Impact of broadening trial eligibility criteria for patients with advanced non–small cell lung cancer: real-world analysis of select ASCO- Friends recommendations. Clin Cancer Res. 2021;27:2430–4.
doi: 10.1158/1078-0432.CCR-20-3857
Gross CP, Mallory R, Heiat A, Krumholz HM. Reporting the recruitment process in clinical trials: who are these patients and how did they get there? Ann Intern Med. 2002;137:10–6.
He Z, Tang X, Yang X, Guo Y, George TJ, Charness N, et al. Clinical trial generalizability assessment in the big data era: a review. Clin Transl Sci. 2020;13:675–84.
doi: 10.1111/cts.12764
Humphreys K, Maisel NC, Blodgett JC, Fuh IL, Finney JW. Extent and reporting of patient nonenrollment in influential randomized clinical trials, 2002 to 2010. JAMA Intern Med. 2013;173:1029.
doi: 10.1001/jamainternmed.2013.496
Humphreys K, Maisel NC, Blodgett JC, Finney JW. Representativeness of patients enrolled in influential clinical trials: a comparison of substance dependence with other medical disorders. J Stud Alcohol Drugs. 2013;74:889–93.
doi: 10.15288/jsad.2013.74.889
Loh Z, Salvaris R, Chong G, Churilov L, Manos K, Barraclough A, et al. Evolution of eligibility criteria for diffuse large B‐cell lymphoma randomised controlled trials over 30 years. Br J Haematol. 2021;193:741–9.
doi: 10.1111/bjh.17436
Van Spall HG, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA. 2007;297:1233–40.
doi: 10.1001/jama.297.11.1233
Khurana A, Mwangi R, Nowakowski GS, Habermann TM, Ansell SM, LaPlant BR, et al. Impact of organ function–based clinical trial eligibility criteria in patients with diffuse large b-cell lymphoma: who gets left behind? J Clin Oncol. 2021;39:1641–9.
doi: 10.1200/JCO.20.01935
Winters AC, Gutman JA, Purev E, Nakic M, Tobin J, Chase S, et al. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Adv. 2019;3:2911–9.
doi: 10.1182/bloodadvances.2019000243
Kim ES, Bruinooge SS, Roberts S, Ison G, Lin NU, Gore L, et al. Broadening eligibility criteria to make clinical trials more representative: american society of clinical oncology and friends of cancer research joint research statement. J Clin Oncol. 2017;35:3737–44.
doi: 10.1200/JCO.2017.73.7916
Kim ES, Uldrick TS, Schenkel C, Bruinooge SS, Harvey RD, Magnuson A, et al. Continuing to broaden eligibility criteria to make clinical trials more representative and inclusive: asco–friends of cancer research joint research statement. Clin Cancer Res. 2021;27:2394–9.
doi: 10.1158/1078-0432.CCR-20-3852
Booth CM, Le Maître A, Ding K, Farn K, Fralick M, Phillips C, et al. Presentation of nonfinal results of randomized controlled trials at major oncology meetings. J Clin Oncol. 2009;27:3938–44.
doi: 10.1200/JCO.2008.18.8771
Del Paggio JC, Berry JS, Hopman WM, Eisenhauer EA, Prasad V, Gyawali B, et al. Evolution of the randomized clinical trial in the era of precision oncology. JAMA Oncol. 2021;7:728.
doi: 10.1001/jamaoncol.2021.0379
Buckley SA, Percival M-E, Othus M, Halpern AB, Huebner EM, Becker PS, et al. A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study. Leuk Lymphoma. 2019;60:1023–9.
doi: 10.1080/10428194.2018.1516036
Percival M-EM, Othus M, Mirahsani S, Gardner KM, Shaw C, Halpern AB et al. Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility. Haematologica. 2021;106:2114–20.
Statler A, Radivoyevitch T, Siebenaller C, Gerds AT, Kalaycio M, Kodish E, et al. The relationship between eligibility criteria and adverse events in randomized controlled trials of hematologic malignancies. Leukemia. 2017;31:1808–15.
doi: 10.1038/leu.2016.374
Statler A, Othus M, Erba HP, Chauncey TR, Radich JP, Coutre S, et al. Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies. Blood. 2018;131:2782–8.
doi: 10.1182/blood-2018-01-826693
Lichtman SM, Harvey RD, Damiette Smit M-A, Rahman A, Thompson MA, Roach N, et al. Modernizing clinical trial eligibility criteria: recommendations of the american society of clinical oncology–friends of cancer research organ dysfunction, prior or concurrent malignancy, and comorbidities working group. J Clin Oncol. 2017;35:3753–9.
doi: 10.1200/JCO.2017.74.4102
Liu R, Rizzo S, Whipple S, Pal N, Pineda AL, Lu M, et al. Evaluating eligibility criteria of oncology trials using real-world data and AI. Nature. 2021;592:629–33.
doi: 10.1038/s41586-021-03430-5